Evidence map›Paper›PMID 42207735›Full record

ArticleCerebrovascular diseases extra2026

Endovascular Therapy for Isolated M2 Occlusion in Patients with Ischemic Stroke: A Propensity Score-Matched Analysis.

Noriyuki Sahara, Go Hashimoto, Kuniyuki Nakamura, Fumi Irie, Takuya Kiyohara, Yoshinobu Wakisaka, Ryu Matsuo, Masahiro Kamouchi, Tetsuro Ago

Abstract readMulticenter StudyComparative Study
In one paragraph

Article in Cerebrovascular diseases extra, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Noriyuki SaharaDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Go HashimotoDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kuniyuki NakamuraDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Fumi IrieDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takuya KiyoharaDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshinobu WakisakaDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryu MatsuoDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, matsuo.ryu.838@m.kyushu-u.ac.jp.
Masahiro KamouchiDepartment of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tetsuro AgoDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEndovascular therapy (EVT) is an established treatment for large vessel occlusion in patients with acute ischaemic stroke; however, its efficacy for medium vessel occlusions, particularly isolated M2 segment occlusions, remains uncertain. As M2 occlusions are relatively proximal among medium vessel occlusions and can cause disabling neurological deficits, clarifying the role of EVT is clinically important. In this study, we aimed to evaluate the efficacy and safety of EVT compared with best medical management (BMM) in patients with acute isolated M2 occlusion using data from a multicentre registry.

methodsWe analysed the data of patients from a multicentre stroke registry who had an isolated M2 occlusion, had arrived within 24 h of onset, and were functionally independent before stroke. Data on baseline demographics, vascular risk factors, stroke characteristics, and treatment were collected. Propensity score matching generated 100 well-balanced pairs of EVT- and BMM-treated patients. The primary outcomes were favourable functional outcomes (modified Rankin Scale [mRS] score of 0-2 or 0-1) and mortality at discharge and 3 months. The secondary outcomes included neurological improvement or deterioration and haemorrhagic complications during hospitalisation.

resultsAmong 594 eligible patients (EVT, n = 118; BMM, n = 476), data from 100 matched pairs were analysed. At 3 months, good functional outcomes (mRS score of 0-2: 49% EVT vs. 46% BMM) and mortality (7% vs. 9%) were comparable, with consistent findings at discharge. EVT was associated with higher rates of any intracranial haemorrhage (46% vs. 21%), although the symptomatic intracranial haemorrhage rates were identical (5%). In exploratory subgroup analyses, a significant interaction with onset-to-door time was observed for mRS score of 0-2 (p = 0.03), whereas no significant interaction was detected for mRS score of 0-1 or mortality.

conclusionIn this multicentre registry of patients with isolated M2 occlusion, EVT was not associated with superior functional outcomes or reduced mortality, compared with BMM. Although exploratory analyses suggested possible heterogeneity of treatment effect according to clinical factors, such as time from onset, these findings should be interpreted cautiously. Overall, the results highlight the heterogeneity of M2 occlusions and underscore the need for adequately powered randomised trials to inform individualised treatment decisions.

Indexed as

Endovascular ProceduresInfarction, Middle Cerebral ArteryIschemic StrokeAgedAged, 80 and overDisability EvaluationFemaleFunctional StatusHumansJapanMaleMiddle AgedPropensity ScoreRecovery of FunctionRegistriesRetrospective StudiesAcute ischaemic strokeBest medical managementEndovascular therapyM2 occlusionPropensity score matching

Identifiers

PMID42207735
PMCPMC13391054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.